Funded Biotechnology Research Startups
The 19 biotechnology research companies shown here span round closes from November 2022 through May 2025, covering stages from Pre-Seed through Series B.
The 19 biotechnology research companies shown here span round closes from November 2022 through May 2025, covering stages from Pre-Seed through Series B. November 2022 is the densest single month in this dataset, accounting for seven of the 19 entries — including Concerto Biosciences ($23M Series A, Cambridge), Sensorium Therapeutics ($30M Series A, Boston), and Rebus Biosystems ($18M Series Unknown, Santa Clara). The most recent close is Native Labs, a London pre-seed company that raised $200K in May 2025.
US cities dominate the geography, with Boston alone appearing for Nanite, Empatica, and Sensorium Therapeutics. London contributes two pre-seed-stage companies — Native Labs and Polari Group. Outside the US and UK, the dataset includes HAON Life Sciences in Dublin, Fresh Inset in Torun (Poland), and TeraCyte Analytics in Caesarea (Israel). Round sizes range from Walela's $50K Series Unknown (Chicago, November 2022) up to Avidicure's $50M Seed (South Holland, Illinois, April 2025). Nine of the 19 rounds carry a "Series Unknown" classification, and two — TeraCyte Analytics and Empatica — did not disclose amounts.
Most recent rounds
19 shownRelated listings
Frequently asked
What are the largest disclosed rounds among these biotechnology research companies?
Avidicure (South Holland, Illinois) leads with a $50M Seed round closed in April 2025. Sensorium Therapeutics (Boston) raised $30M in a Series A in November 2022, followed by Concerto Biosciences (Cambridge, MA) at $23M Series A the same month. Living Carbon (San Francisco) closed a $21M Series A in January 2023.
Which cities show the most biotechnology research funding activity in this data?
Boston appears three times — Nanite (Seed, $6M), Empatica (Series B, undisclosed), and Sensorium Therapeutics (Series A, $30M). London accounts for two companies: Native Labs (Pre-Seed, $200K) and Polari Group (Pre-Seed, $540K). Cambridge, Massachusetts adds Concerto Biosciences at $23M Series A.
How common is the 'Series Unknown' classification in this segment?
Nine of the 19 entries carry a Series Unknown designation, making it the most frequent round type shown. This group includes companies with a wide range of disclosed amounts — from Cybele Microbiome's $890K to Avidicure's $50M Seed — as well as TeraCyte Analytics, which did not disclose its amount.
Which companies have undisclosed round sizes?
Two companies did not disclose amounts: TeraCyte Analytics (Caesarea, Israel, Series Unknown, June 2023) and Empatica (Boston, Series B, November 2022).
How international is the biotechnology research funding shown here?
Thirteen of the 19 companies are US-based. The remaining six are headquartered in the UK (Native Labs and Polari Group, both London), Ireland (HAON Life Sciences, Dublin), Poland (Fresh Inset, Torun), and Israel (TeraCyte Analytics, Caesarea). No single non-US country accounts for more than two companies in this dataset.
What does the timeline of funding activity look like across this dataset?
Seven of the 19 rounds closed in November 2022 alone, representing the sharpest concentration in the dataset. Activity then spreads across 2023 — with five closings from January through June — before thinning in 2024 and 2025. The most recent entry is Native Labs' May 2025 Pre-Seed, and only two companies (Native Labs and Avidicure) have 2025 close dates.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.